Key result
Paclitaxel-coated balloons reduce late lumen loss ~58% vs uncoated balloons for DES restenosis.
Why the study?
The impact of paclitaxel-coated balloon angioplasty compared with uncoated balloon angioplasty for treatment of drug-eluting stent restenosis was not well defined.
Does paclitaxel-coated balloon angioplasty reduce late lumen loss compared to uncoated balloon angioplasty in patients with drug-eluting stent restenosis?
RCT (n=110)
Single-blind
Randomized
Yes
Does paclitaxel-coated balloon angioplasty reduce late lumen loss compared to uncoated balloon angioplasty in patients with drug-eluting stent restenosis?
Answers are grounded in this paper and cite their sources.
Paclitaxel-coated balloon angioplasty significantly reduces late lumen loss and composite clinical endpoints compared to plain balloon angioplasty for the treatment of drug-eluting stent restenosis.
OBJECTIVES: This study sought to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty alone. BACKGROUND: Drug-coated balloon angioplasty is associated with favorable results for treatment of bare-metal stent restenosis. METHODS: In this prospective, single-blind, multicenter, randomized trial, the authors randomly assigned 110 patients with drug-eluting stent restenoses located in a native coronary artery to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty. Dual antiplatelet therapy was prescribed for 6 months. Angiographic follow-up was scheduled at 6 months. The primary endpoint was late lumen loss. The secondary clinical endpoint was a composite of cardiac death, myocardial infarction attributed to the target vessel, or target lesion revascularization. RESULTS: There was no difference in patient baseline characteristics or procedural results. Angiographic follow-up rate was 91%. Treatment with paclitaxel-coated balloon was superior to balloon angioplasty alone with a late loss of 0.43 ± 0.61 mm versus 1.03 ± 0.77 mm (p < 0.001), respectively. Restenosis rate was significantly reduced from 58.1% to 17.2% (p < 0.001), and the composite clinical endpoint was significantly reduced from 50.0% to 16.7% (p < 0.001), respectively. CONCLUSIONS: Paclitaxel-coated balloon angioplasty is superior to balloon angioplasty alone for treatment of drug-eluting stent restenosis. (PEPCAD DES-Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter [PEPCAD-DES]; NCT00998439).
No takes yet. Share an insight, caveat, or question.
Rittger et al. (2012) conducted an RCT in Drug-eluting stent restenosis (n=110). Paclitaxel-coated balloon angioplasty vs. Uncoated balloon angioplasty was evaluated on Late lumen loss (p=<0.001). Paclitaxel-coated balloon angioplasty was superior to uncoated balloon angioplasty for drug-eluting stent restenosis, reducing late lumen loss.
Synapse has enriched 10 related papers. Consider them for comparative context: